List of Excipients in Branded Drug DALVANCE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	DALVANCE	dalbavancin	57970-100	LACTOSE MONOHYDRATE
Allergan Inc	DALVANCE	dalbavancin	57970-100	MANNITOL

# DALVANCE Excipient Strategy and Commercial Opportunities for Dalbavancin

Last updated: August 7, 2026

DALVANCE is an injectable dalbavancin product with a narrow excipient profile, a defined reconstitution process, and a major commercial limitation: the current presentation requires healthcare-provider preparation and dilution before infusion. The strongest excipient-led opportunities are ready-to-use or ready-to-administer formats, improved stability, alternative diluents, home-infusion compatibility, and pediatric dose flexibility. Oral delivery and simple subcutaneous conversion are technically higher-risk programs because dalbavancin is a large glycopeptide antibiotic requiring parenteral administration.

What excipients are used in DALVANCE?

DALVANCE is supplied as a sterile lyophilized powder in single-dose vials. Mannitol is the principal inactive ingredient identified in the U.S. prescribing information. The product is reconstituted with Sterile Water for Injection and diluted only with 5% Dextrose Injection under the labeled preparation instructions.[1]

Product attribute	DALVANCE characteristic
Active ingredient	Dalbavancin hydrochloride
Dosage form	Lyophilized powder for intravenous infusion
Strengths	350 mg and 500 mg single-dose vials
Primary excipient	Mannitol
Reconstitution diluent	Sterile Water for Injection
Labeled infusion diluent	5% Dextrose Injection
Administration	Intravenous infusion over approximately 30 minutes
Approved use	Acute bacterial skin and skin structure infections
Pediatric use	Patients three months and older, subject to labeled dosing
Key preparation constraint	Saline-based dilution is not the labeled compatibility pathway

The 500 mg adult vial is used for the single-dose 1,500 mg regimen or the two-dose 1,000 mg followed one week later by 500 mg regimen. The 350 mg vial supports pediatric weight-based dosing and selected adult dose calculations.[1]

Mannitol likely performs several formulation functions: bulking the lyophilized cake, improving cake structure, supporting dose uniformity, and contributing to reconstitution performance. The limited excipient composition reduces inactive-ingredient complexity but leaves fewer conventional formulation levers for improving solubility or stabilizing a liquid product.

What formulation problems create commercial opportunities for DALVANCE?

The largest opportunity is to reduce preparation burden without changing the clinical regimen. Current product handling requires vial reconstitution, dilution, aseptic preparation, and infusion. That creates labor, medication-error, pharmacy-compounding, and administration costs.

Current formulation constraints

The commercial formulation has four practical constraints:

1. It is not supplied as a ready-to-use liquid.
2. It requires a separate reconstitution step.
3. The labeled dilution vehicle is 5% Dextrose Injection.
4. The product is administered intravenously in a clinical or infusion setting.

These constraints matter because DALVANCE’s clinical value depends in part on avoiding prolonged daily intravenous treatment. Any preparation requirement that forces hospital or infusion-center involvement reduces the economic benefit of the long-acting regimen.

Highest-value excipient programs

Opportunity	Commercial value	Technical difficulty	Likely development path
Ready-to-use premixed infusion	High	Medium to high	Reformulated drug product
Extended refrigerated liquid stability	High	High	New formulation and stability package
Room-temperature liquid stability	High	High	New formulation, container, and compatibility work
Normal-saline compatibility	Medium to high	Medium	Compatibility and product-label expansion
Smaller-volume concentrated infusion	High	High	New concentration and infusion study
Pre-filled syringe or cartridge	Medium	High	Device-product combination
Improved pediatric presentation	Medium	Medium	New strength or dosing system
Subcutaneous depot	Very high	Very high	New route, formulation, and clinical program
Oral formulation	Very high	Extremely high	New delivery technology and clinical development

What excipient strategy could support a ready-to-use DALVANCE product?

A ready-to-use product would need a liquid formulation that maintains dalbavancin potency, controls aggregation, limits particulates, preserves sterility, and remains compatible with the container and infusion set.

Candidate formulation levers

A reformulation program could evaluate:

• pH adjustment within the drug’s stability window;
• buffering systems with low interaction risk;
• tonicity agents other than or in combination with mannitol;
• surfactants to limit interfacial aggregation;
• amino-acid or polyol stabilizers;
• chelating agents where trace metals contribute to degradation;
• low-binding container and administration materials;
• nitrogen headspace or oxygen-control strategies;
• higher-concentration formulations for lower infusion volume.

Dalbavancin is a glycopeptide antibiotic with a complex molecular structure. The principal risks are likely to include aggregation, degradation during liquid storage, adsorption to surfaces, particulate formation, and sensitivity to temperature or pH excursions. Excipients that improve one property can impair another. For example, a surfactant may reduce surface-induced aggregation but create new oxidation, extractables, or tolerability concerns.

A commercially attractive target would be a single-container, pharmacy-ready infusion that remains stable under refrigerated conditions for a clinically meaningful period. Room-temperature stability would have greater value because it would simplify distribution and reduce cold-chain handling, but it would impose a higher formulation and packaging burden.

What formulations are protected by DALVANCE patents?

Patent protection for DALVANCE must be separated into active-ingredient, formulation, manufacturing, dosage-regimen, and method-of-use claims. The original dalbavancin composition and antibacterial-use patents are distinct from later product-specific claims.

Patent category	Relevance to an excipient program
Dalbavancin composition patents	May affect use of the active ingredient itself
Lyophilized formulation patents	May cover excipient ratios, cake structure, or reconstitution
Liquid formulation patents	Could cover stabilizers, pH, concentration, and storage
Container or device patents	May affect prefilled, cartridge, or premixed systems
Method-of-use patents	Could cover dosing schedules or infection indications
Manufacturing patents	May cover fermentation, purification, or drug-substance processing

An excipient strategy does not automatically avoid active-ingredient or formulation patents. A company developing a new DALVANCE presentation would need a claim-by-claim freedom-to-operate review covering U.S. and foreign patent families, continuation applications, terminal disclaimers, and Orange Book-listed patents.

The FDA Orange Book is the controlling public source for listed patents and regulatory exclusivity associated with approved small-molecule products.[2] For a reformulated product, the relevant analysis would also include whether the product is an amended presentation of the existing NDA or a separately protected drug product.

When does DALVANCE lose exclusivity?

DALVANCE was approved by the FDA in May 2014 for acute bacterial skin and skin structure infections.[3] Its original regulatory exclusivity periods have expired. FDA pediatric exclusivity associated with the product also does not create a current barrier to development of alternative dalbavancin products.

The commercially relevant protection question is therefore no longer limited to the original approval date. It concerns:

• remaining listed patents;
• unexpired formulation or manufacturing patents;
• litigation or settlement restrictions;
• regulatory pathway for an abbreviated or supplemental product;
• data requirements for a new dosage form or route.

A generic intravenous powder-for-injection product could face a different regulatory and technical burden from a ready-to-use liquid. The latter would likely require more than a simple copy of the existing lyophilized presentation because the excipient system, container, stability profile, and administration instructions would differ.

What is the Orange Book status of DALVANCE?

DALVANCE is an FDA-approved prescription drug marketed under an NDA held by Melinta Therapeutics.[1,3] The Orange Book should be reviewed for the current list of patents, patent-use codes, exclusivity codes, and any changes to the NDA record.[2]

For commercial planning, the Orange Book review should distinguish:

• patents covering the approved product;
• patents covering only specific methods of use;
• patents with expired terms;
• patents subject to pediatric extensions;
• patents that may be challenged through Paragraph IV certification.

A Paragraph IV challenge to a listed patent would create potential Hatch-Waxman litigation. The commercial impact would depend on the challenged patent claims, the filing date, the 30-month stay, any settlement terms, and whether the proposed product is limited to non-patented uses.

Which companies are challenging DALVANCE?

A definitive list of active Paragraph IV filers and litigation defendants requires a current FDA and court-docket review. No generic challenge should be treated as commercially active solely because a company has announced a development program.

The relevant records are:

• FDA Paragraph IV certification and notification records;
• Orange Book patent listings;
• Abbreviated New Drug Application litigation complaints;
• district-court docket activity;
• Federal Circuit appeals;
• settlement and license agreements.

The key distinction is between a generic intravenous dalbavancin product and a differentiated product with a new formulation. A Paragraph IV challenge may target the existing vial presentation, while a ready-to-use formulation could require separate formulation patents and potentially a different regulatory strategy.

How strong is the DALVANCE patent estate for excipient innovation?

The estate is more vulnerable to excipient-led competition than a product protected by multiple active formulation and device patents. The original lyophilized vial uses a simple excipient system, which may limit opportunities to block alternative compositions. A competitor could seek protection around:

• a liquid dalbavancin composition;
• a defined pH range;
• a stabilizer combination;
• a high-concentration preparation;
• an extended-storage profile;
• a prefilled administration system;
• compatibility with saline or other infusion vehicles;
• a subcutaneous depot formulation.

Patent strength would depend on whether claims cover broad functional concepts or narrow, experimentally supported compositions. Broad claims to “stabilized dalbavancin” may face written-description, enablement, or obviousness challenges. Narrow claims tied to specific excipient ratios, stability thresholds, and container systems may be easier to defend but offer less competitive coverage.

How does DALVANCE compare with competing long-acting antibiotics?

DALVANCE competes with other long-acting or outpatient-oriented antibiotics, particularly ORBACTIV, which contains oritavancin, and standard agents used through outpatient parenteral antimicrobial therapy.

Attribute	DALVANCE	ORBACTIV	Standard daily IV therapy
Active ingredient	Dalbavancin	Oritavancin	Varies
Administration concept	One dose or two doses	Single IV dose	Repeated administration
Current formulation	Lyophilized vial	Lyophilized vial	Multiple formats
Excipient opportunity	Premix, stability, alternative diluent	Similar preparation simplification	Often lower
Main commercial advantage	Reduced dosing frequency	Single-dose treatment	Familiarity and lower acquisition cost
Main limitation	Product cost and preparation	Product cost and monitoring considerations	Labor and access burden

DALVANCE’s excipient opportunity is strongest where reduced administration frequency is already clinically valuable but preparation complexity remains a barrier.

What generic launch risks exist for DALVANCE?

The most credible generic launch scenarios are:

Scenario 1: Copy of the lyophilized vial

This is the most direct competition. It would likely compete primarily on acquisition price. The product would retain the operational burden of reconstitution and dilution.

Scenario 2: Improved vial presentation

A competitor could preserve the lyophilized format while improving reconstitution time, cake integrity, vial fill, or pediatric dose flexibility. This strategy would offer moderate differentiation but limited protection from price competition.

Scenario 3: Ready-to-use liquid infusion

This is the most commercially disruptive excipient strategy. It could capture hospitals, emergency departments, ambulatory infusion providers, and home-infusion networks that value simplified preparation.

Scenario 4: Alternative-route product

A subcutaneous or intramuscular formulation could expand administration outside infusion centers. It would require substantial pharmacokinetic, local-tolerability, and clinical validation.

What licensing opportunities exist for DALVANCE excipient technology?

The most practical licensing targets are technologies with demonstrated compatibility with complex injectable biologics or antibiotics. Relevant assets include:

• lyophilization and cake-forming platforms;
• liquid stabilization systems;
• low-shear reconstitution technologies;
• ready-to-administer infusion bags;
• prefilled syringe and cartridge systems;
• subcutaneous delivery devices;
• oxygen-control packaging;
• extractables and leachables mitigation systems.

A licensing deal would have greater value if it included composition-of-matter or formulation patent coverage, scalable manufacturing, and regulatory precedent. A platform excipient without dalbavancin-specific stability data would have limited immediate value.

What FDA pathway applies to a new DALVANCE formulation?

A new manufacturer seeking to copy the approved injectable product would generally evaluate an abbreviated pathway under Section 505(j), subject to the product’s dosage form, route, active ingredient, strength, and sameness requirements.[4]

A materially different product, such as a ready-to-use liquid, concentrated infusion, new route, or device-enabled product, may require a 505(b)(2) strategy. The pathway would depend on the extent of formulation, delivery-system, pharmacokinetic, local-tolerability, and clinical differences from the approved product.

The FDA would likely focus on:

• pharmaceutical equivalence;
• bioequivalence or comparative pharmacokinetics;
• sterility and particulate control;
• container-closure integrity;
• infusion compatibility;
• extractables and leachables;
• stability;
• dose preparation and administration;
• pediatric dosing where applicable.

What is the revenue exposure from excipient-based competition?

Revenue exposure is concentrated in settings where DALVANCE is selected to avoid hospital admission, prolonged intravenous access, or daily outpatient infusion. A lower-cost generic vial would pressure price. A better formulation could instead expand the market by reducing preparation and administration costs.

The commercial value of a ready-to-use product would be highest in:

• emergency departments treating patients for discharge;
• hospital-at-home programs;
• skilled nursing facilities;
• outpatient infusion centers;
• infectious-disease clinics;
• correctional and rural healthcare systems;
• pediatric settings requiring weight-based dosing;
• health systems with limited pharmacy compounding capacity.

A formulation that permits rapid pharmacy release and home administration could compete on total treatment cost rather than vial price alone.

Key Takeaways

• DALVANCE uses a simple excipient system centered on mannitol in a lyophilized intravenous vial.
• The main commercial weakness is preparation complexity, not the dosing concept.
• Ready-to-use liquid infusion is the highest-value excipient opportunity.
• Alternative diluent compatibility, especially saline compatibility, could improve operational adoption.
• Concentrated and lower-volume presentations could reduce infusion and pharmacy-handling burden.
• Subcutaneous delivery has greater upside but requires a new clinical and regulatory program.
• Original regulatory exclusivity has expired; current patent and litigation status must be assessed through the Orange Book and court records.
• A generic lyophilized vial would likely compete on price, while a stabilized liquid or device-enabled product could compete on total treatment economics.
• Formulation claims should focus on defined compositions, stability performance, container compatibility, and administration advantages.
• The FDA pathway will depend on whether the product is a pharmaceutically equivalent copy or a materially different formulation or delivery system.

FAQs About DALVANCE Excipient and Formulation Strategy

Can DALVANCE be diluted in normal saline?

The U.S. label specifies dilution with 5% Dextrose Injection. A saline-based product would require separate compatibility, stability, and labeling support.[1]

Does DALVANCE contain polyethylene glycol?

Polyethylene glycol is not identified as an inactive ingredient in the U.S. DALVANCE prescribing information. Mannitol is the principal listed excipient.[1]

Could DALVANCE be supplied in a prefilled syringe?

Potentially, but a prefilled syringe would require liquid stability, container compatibility, sterility, extractables, device-performance, and administration studies. A syringe presentation would not be a simple packaging change.

Is a liquid DALVANCE formulation likely to be patentable?

It could be patentable if the formulation has a novel and non-obvious combination of excipients, concentration, pH, storage stability, container system, or administration performance. Broad claims without supporting data would face greater validity risk.

Could dalbavancin be reformulated for oral use?

An oral product would face major absorption and delivery barriers associated with dalbavancin’s large glycopeptide structure. It would require a new delivery technology and would likely follow a more extensive clinical development pathway than an injectable reformulation.

References

1. U.S. Food and Drug Administration. (2024). DALVANCE (dalbavancin hydrochloride) for injection, prescribing information. Melinta Therapeutics, LLC.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.

3. U.S. Food and Drug Administration. (2014). FDA approves Dalvance to treat acute bacterial skin and skin structure infections.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and the 505(j) pathway.